ASH 2026: 5 Hematology Abstracts That Could Move Stocks

Every biotech investor knows ASCO moves stocks. Fewer screen ASH systematically, and that is the edge. ASH, the American Society of Hematology annual meeting, runs December 12-15 in New Orleans this year. The trade fires weeks before the podium. Regular abstract titles drop November 4 at 9:00 a.m. Eastern, and late-breakers go live December 7. If you wait for the presenter to step up, the stock has already gapped. This is the forward twin of the ESMO 2026 preview, transposed from oncology to blood cancers.

The pattern repeats every December. A mid-cap hematology name drops a dataset that surprises the Street, the stock gaps 15-30% overnight, and the mega-cap Keytruda and bispecific updates that dominate ASH headlines barely twitch. The edge is screening the small and mid-cap names where the data actually changes the thesis. Here are five to watch, ranked by stock-moving potential.

1. Immix Biopharma NXC-201: The 95% CR That Needs to Hold Up

Immix Biopharma closed at $10.97, a $785 million market cap built entirely on one asset: NXC-201, an autologous BCMA-directed CAR-T for relapsed or refractory AL amyloidosis. The published data show a 95% complete hematologic response rate in 19 of 20 evaluable patients in the NEXICART-2 trial, with no neurotoxicity and only low-grade cytokine release syndrome. The company guided to a late September 2026 data update, which lands in the window where an ASH late-breaker would be submitted. That makes ASH the obvious venue for the full dataset.

The abstract to screen for is the full NEXICART-2 readout across the entire 45-patient trial, not the 20-patient interim. The re-rate thesis is arithmetic. AL amyloidosis affects roughly 38,500 US patients, there is zero approved CAR-T in the indication, and at $400,000 per dose with 10% US penetration, peak sales approach $1.5 billion, roughly 2x Immix’s current market cap. A 95% CR that holds in the full dataset, with organ response and durability attached, moves the stock toward the $1.5-3 billion peak sales range. Immix is already planning a randomized Phase 3 in newly diagnosed patients and a BLA on the registrational design.

The risk is the small sample. A 95% CR rate built on 20 patients can slip as the denominator grows, and cardiac decompensation during cytokine release syndrome is the specific safety concern in a population whose hearts are already amyloid-infiltrated. The full NXC-201 AL amyloidosis story and the NEXICART-2 trial design are covered; ASH is the checkpoint where a single-arm Phase 2 either becomes a registrational asset or stays an anecdote.

2. Karyopharm Selinexor: The Filing Decision, Not the Data

Karyopharm closed at $1.62 with a market cap near $37 million. The myelofibrosis thesis is already public: selinexor plus ruxolitinib hit SVR35 at week 24 in 49.8% of patients versus 28.0% for ruxolitinib alone (odds ratio 2.58, p<0.0001) in the Phase 3 SENTRY trial, while the co-primary symptom endpoint missed. The FDA agreed in writing that SVR35 qualifies as a reasonably likely surrogate, which enabled the accelerated approval filing. Karyopharm submitted the sNDA on August 31 and requested priority review.

The catalyst that matters is not an ASH abstract. It is the FDA’s 60-day filing review decision, expected in the fourth quarter of 2026, which likely lands in late October, before ASH abstracts even go live. If the FDA accepts the filing and grants priority review, Karyopharm re-rates on the path to a decision in the first half of 2027. If not, the wait extends and the stock sits near cash value. This is the highest reward-per-dollar name on the shelf precisely because the market is pricing near-zero probability of success.

The ASH watch item is different: long-term overall survival follow-up from SENTRY, which is the confirmatory data the FDA will ultimately require. The topline OS signal was promising but immature, with a hazard ratio of 0.43 and a nominal one-sided p of 0.022 at roughly 12 months of follow-up. Longer follow-up at ASH would either firm up that signal or unwind it. The selinexor filing and the broader hematology shelf are covered; the trade here is the filing decision, with ASH as the confirmation layer behind it.

3. Bristol Myers Arlo-cel: The Full QUINTESSENTIAL Number

Bristol Myers Squibb said on September 8 that arlo-cel, its GPRC5D-directed CAR-T, met the primary overall response rate endpoint and the key secondary complete response rate endpoint in the registrational Phase 2 QUINTESSENTIAL trial in quadruple-class exposed relapsed or refractory myeloma. It withheld the actual number. That missing number is the trade. The Phase 1 benchmark is already public: an 87% overall response rate and 53% complete response rate across 84 patients, with a median progression-free survival of 18.3 months. QUINTESSENTIAL full data is promised for an upcoming medical meeting, and because the abstract submission deadline passed in early August, the topline can only surface as a late-breaker, which is exactly the December 7 slot.

The target context is the fight against Johnson and Johnson’s Talvey, the approved GPRC5D bispecific. Arlo-cel would be the first GPRC5D CAR-T, a single infusion against Talvey’s chronic dosing, in a population that has already exhausted BCMA-directed therapy. The catch is that Bristol Myers is a $128 billion market cap, so an arlo-cel approval moves the ticker roughly zero basis points. The re-rate shows up in the cell-therapy franchise multiple, not the daily price. For investors who want the pure-play version of the GPRC5D thesis, there is no clean US-listed one; that is the limitation. The GPRC5D arlo-cel topline and the QUINTESSENTIAL trial are covered. Screen for the late-breaker on December 7.

4. CRISPR Therapeutics CTX112: The Autoimmune CAR-T Safety Debate

CRISPR Therapeutics closed at $54.23, a $5.24 billion market cap. Its zugo-cel, an allogeneic CD19 CAR-T, is the watch item, and the read-through is about safety more than efficacy. The autoimmune CAR-T thesis hit a wall in late August when Novartis paused eight rap-cel autoimmune trials after three deaths from immune effector cell-associated hemophagocytic syndrome, and Bristol Myers paused enrollment on its zola-cel program over inflammatory events. The question ASH has to answer is whether the off-the-shelf format CRISPR uses can deliver the durable lupus and myositis remissions without the severe inflammatory syndrome that killed the autologous programs.

CRISPR has guided to additional autoimmune and hematologic malignancy updates in the second half of 2026, and ASH is the natural venue. The prior data are encouraging: the first SLE patient maintained drug-free DORIS remission through month 12, and in B-cell lymphomas zugo-cel showed a 90% overall response rate and 70% complete response rate at the highest dose. The re-rate hinges on whether the autoimmune data at ASH shows deep B-cell depletion with clean safety in a larger cohort. If it does, CRISPR re-rates as the safer autoimmune cell therapy. If it shows the same inflammatory signals, the whole theme stays on ice and the selloff in autoimmune CAR-T names extends. The risk is venue: CRISPR could hold the update for a rheumatology meeting instead, and the read-through never lands at ASH. The CTX112 program status is covered; ASH is the next data checkpoint.

5. The Autoimmune CAR-T Shelf: Read It Through the Leaders

The fifth position is a theme, not a single ticker. The three-death rap-cel pause reset expectations for the entire autoimmune cell therapy category, and ASH is where the field either rehabilitates the thesis or buries it. The names to screen are the ones that can actually re-rate on a positive read: CRISPR’s zugo-cel, as covered, plus the private and academic programs that will populate the late-breaker slate. The mega-cap read-through, from Novartis and Bristol Myers, is noise at their scale. The investable signal is whether any allogeneic or lower-intensity construct shows remission without the hemophagocytic syndrome, because that single data point would restart the flow of capital into the category after a month of outflows.

The Mega-Cap Filter

This list intentionally excludes the Keytruda-in-lymphoma, Roche-bispecific, and J&J Talvey/Tecvayli updates that will dominate ASH headlines. Those move zero basis points on $100-400 billion market caps. Bristol Myers’ mezigdomide, which pairs with carfilzomib and dexamethasone and carries a May 2027 PDUFA, is the clearest example: SUCCESSOR-2 is already published in The Lancet with an 18.0-month versus 8.3-month median PFS benefit, so any ASH follow-up is confirmation, not a catalyst. The filter is simple: if the market cap exceeds $100 billion and the indication is a single blood cancer, the data does not move the stock.

The Catalyst-Consumed Caveat

The same lesson from the ESMO preview’s Jideytro entry applies here. Some hematology catalysts will resolve between now and ASH. Karyopharm’s filing acceptance decision, expected in Q4 2026, is the live example: if the FDA accepts the selinexor sNDA with priority review in late October, that catalyst is consumed before abstracts drop, and the ASH story becomes follow-up data rather than a binary. Verify approval and filing status before you trade any of these names on abstract day.

The conference playbook is covered in the biotech conference trading guide: abstract release is the trade date, position size 1-2% of portfolio per binary event, and IV crush after the abstract drop is real whether the data is good or bad. The 24-hour rule applies. Do not hold a conference catalyst position past the first trading day after abstract release unless you have a thesis on the follow-up data.

The verdict: screen for the Immix NXC-201 full dataset and the CRISPR zugo-cel autoimmune data first. Those are the two names where ASH 2026 data actually re-rates the stock. Karyopharm’s filing decision is the third, and it will likely resolve before the meeting even starts.